GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Huadong Medicine Co Ltd (SZSE:000963) » Definitions » Capex-to-Operating-Income

Huadong Medicine Co (SZSE:000963) Capex-to-Operating-Income : 0.42 (As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Huadong Medicine Co Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Huadong Medicine Co's Capital Expenditure for the three months ended in Mar. 2024 was ¥-472.27 Mil. Its Operating Income for the three months ended in Mar. 2024 was ¥1,125.32 Mil.

Hence, Huadong Medicine Co's Capex-to-Operating-Income for the three months ended in Mar. 2024 was 0.42.


Huadong Medicine Co Capex-to-Operating-Income Historical Data

The historical data trend for Huadong Medicine Co's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Huadong Medicine Co Capex-to-Operating-Income Chart

Huadong Medicine Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.41 0.45 0.27 0.36 0.43

Huadong Medicine Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.38 0.20 0.38 0.83 0.42

Competitive Comparison of Huadong Medicine Co's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, Huadong Medicine Co's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Huadong Medicine Co's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Huadong Medicine Co's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Huadong Medicine Co's Capex-to-Operating-Income falls into.



Huadong Medicine Co Capex-to-Operating-Income Calculation

Huadong Medicine Co's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-1606.618) / 3765.55
=0.43

Huadong Medicine Co's Capex-to-Operating-Income for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-472.273) / 1125.318
=0.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Huadong Medicine Co  (SZSE:000963) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Huadong Medicine Co Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Huadong Medicine Co's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Huadong Medicine Co (SZSE:000963) Business Description

Traded in Other Exchanges
N/A
Address
468 Yan’an Road, Floor 7, 9 and 10, Gate No. 1, Building No. 1, Hangzhou, CHN, 310006
Huadong Medicine Co Ltd is engaged in the production and sales of antibiotics, proprietary Chinese medicine, chemical synthetic medicine and genetic engineering drugs products. It is also engaged in the wholesale, retail and distribution business of Chinese and western medicine, Chinese herbal medicine, medical apparatus, and instruments. The main business of the company is divided into pharmaceutical business sales and the industry of pharmaceutical. The product portfolio of the company includes Corbrin capsule, Cymusi, New Cyspin, Kasiping, Panlisu, Acarbose, and others.
Executives
He Ru Fen Supervisors
Hu Bao Zhen Supervisors
Zhou Shun Hua Executives
Shao Ling Min Supervisors
Wan Ling Ling Executives
Fu Hang Director
Yue Jin Director
Chen Bo Secretary Dong
Qin Yun Supervisors
Li Bang Liang Directors, executives
Zhou Jin Bao Directors, executives

Huadong Medicine Co (SZSE:000963) Headlines

No Headlines